Effect of Inhaled Corticosteroid Therapy Step-Down and Dosing Regimen on Measures of Asthma Control by Price, David et al.
Open AccessResearch Article
Price et al., J Aller Ther 2013, 4:1
DOI: 10.4172/2155-6121.1000126
Volume 4 • Issue 1 • 1000126
J Aller Ther
ISSN:2155-6121  JAT an open access journal 
Keywords: Adherence; Asthma; Controller therapy; Exacerbation;
Inhaled corticosteroids; Medication regimen; Step-down
Abbreviations: BD: Twice Daily; BMI: Body Mass Index; ICS:
Inhaled Corticosteroid; IQR: Inter Quartile Range; LABA: Long-
Acting β-Agonist; LTRA: Leukotriene Receptor Antagonist; NSAID: 
Nonsteroidal Anti-Inflammatory Drug; QD: Once Daily; SABA: Short-
Acting β-Agonist
Introduction
Controller therapy for persistent asthma should be administered at 
the minimum dose necessary to control symptoms and minimize risk 
of future exacerbations. For patients whose asthma is well-controlled, 
asthma management guidelines recommend gradually stepping down 
therapy to identify the lowest dose needed to maintain asthma control 
[1-3]. While the guidelines concur on the schedule of step-down (every 
3 months), there is little published evidence regarding outcomes after 
stepping down therapy [1-5]. 
The time of step-down could be an opportunity to change the 
frequency of asthma controller administration or to simplify the 
regimen. Minimizing medication burden and impact of the asthma 
controller regimen for patients with well-controlled asthma may 
improve adherence and maintain or even improve treatment outcomes. 
There is robust evidence for other chronic diseases such as diabetes and 
HIV/AIDS that reducing the dose frequency can improve medication 
adherence [6]. For respiratory conditions, however, few studies have 
rigorously examined adherence in relation to dosing regimen, especially 
for once-daily versus twice-daily administration, although the findings 
suggest that complex regimens may result in lower adherence [6]. 
Recently, in a large pragmatic trial, significantly better adherence rates 
were recorded with a once-daily rather than twice-daily regimen of 
mometasone furoate for patients with asthma [7].
The objective of this study was to evaluate the effect of dose 
frequency and baseline factors predictive of loss of asthma control at 
the time of inhaled corticosteroid (ICS) dose step-down in a real-life, 
UK primary care population. We sought to characterize and compare 
clinical profiles for patients on controller asthma therapy who were 
stepped down in ICS dose to once-daily (QD) or twice-daily (BD) 
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Abstract
Background: Asthma guidelines recommend stepping down therapy to the lowest dose that maintains asthma 
control. 
Objective: We sought to evaluate the effect of dosing frequency and baseline patient and treatment-related 
factors on database markers of asthma control after inhaled corticosteroid (ICS) dose step-down.
Methods: This retrospective observational study evaluated primary care patients (4-80 years old) with asthma 
prescribed twice-daily (BD) ICS (n=26,834) or ICS/long-acting β-agonist (LABA; n=20,814) for ≥ 1 year before ≥ 50% 
step-down in ICS dose, when they were switched to once-daily (QD) or remained on BD therapy. Study endpoints 
included exacerbations (oral corticosteroid prescription, unscheduled asthma-related hospital attendance, or general 
practice consultation for lower respiratory tract infection) and medication adherence.
Results: Significant improvements in most endpoints were recorded during the year after step-down, as 
compared with the prior year (baseline). The proportion of patients with no exacerbation during the baseline year 
vs. the year after step-down was as follows (p<0.001 for all comparisons): QD ICS cohort (73% baseline vs. 81% 
after step-down); BD ICS cohort (67% vs. 77%); QD ICS/LABA cohort (60% vs. 64%); BD ICS/LABA cohort (55% 
vs. 65%). Adherence improved significantly after step-down for all cohorts, most markedly for QD cohorts; and 
the average daily ICS dose as consumed by patients was higher for all but the QD ICS/LABA cohort despite the 
reduction in prescribed dose. Factors predicting loss of asthma control after step-down for patients controlled at 
baseline in either or both ICS and ICS/LABA populations included obesity, smoking, comorbid rhinitis, comorbid 
gastroesophageal reflux disease, and, during the baseline year, ≥ 7 short-acting β-agonist prescriptions, mean 
consumed ICS dose of ≥ 800 µg/day, and ≥ 4 primary care consultations.
Conclusion: Stepping down therapy is a valid management option and may improve asthma-related outcomes. 
Some improvements may result from increased adherence, particularly among patients switched to QD therapy.
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administration; to compare patient profiles between the year before 
and the year after step-down; and to determine which demographic 
and baseline characteristics predicted a loss of asthma control during 
the year after step-down for patients who were well-controlled the prior 
year. 
Methods
Data sources and patients
This retrospective observational study was an analysis of clinical 
data drawn from two primary care databases in the United Kingdom 
(UK), the General Practice Research Database (GPRD) and the 
Optimum Patient Care Research Database (OPCRD). The GPRD is 
now incorporated into the Clinical Practice Research Data link (CPRD) 
[8] but at the time of our study was managed by the UK Medicines 
and Healthcare products Regulatory Agency (MHRA) and contained 
de-identified active medical record data for approximately 5 million 
patients from 500 primary care practices throughout the UK [9-11]. 
The OPCRD is a UK respiratory dataset containing anonymized, 
longitudinal, research-quality clinical records and patient-reported 
outcome data from practices that subscribe to OPC for respiratory 
review services; at the time of the study, the OPCRD included 341,000 
patients at 176 practices [12]. We analyzed GPRD data from 1991 
through June 2007 and OPCRD data from 1990 through 2010, with no 
overlap in patients between the two databases. 
For each eligible patient, we studied a 25-month period comprising 
1 year for patient characterization before ICS dose step-down (on the 
index date) and a 1-year analysis period that began 1 month after step-
down, thereby to exclude patients who rejected the step-down. Thus, 
to be included in the study, patients were required to have at least 25 
months of continuous data. Eligible patients were those who during the 
baseline year received, according to physician prescribing instructions, 
BD controller therapy for asthma-as either ICS monotherapy or 
ICS plus long-acting β-agonist (LABA) in separate or combination 
inhalers-followed on the index date by a prescription for ≥ 50% 
reduction (step-down) in ICS dose delivered by the same inhaler device 
type and pack size as during the baseline year. Patients could be on any 
ICS dose during baseline and, on the index date, could be stepped down 
to either BD or QD controller therapy. Prescriptions for separate ICS 
and LABA inhalers had to be separated by no more than 2 months as 
an indicator of concurrent prescribing for patients assigned to the ICS/
LABA population.
We studied patients with asthma who were 4-80 years old, including 
only non-smokers 61-80 years old. To support the asthma diagnosis, 
patients had to have either a diagnostic code for asthma in the database 
or to have received two or more prescriptions for asthma therapies at 
different points in time during the baseline year. In addition, patients 
had to have evidence of current asthma therapy, defined as receipt of at 
least two separate prescriptions for asthma controller therapy during 
the outcome year, including the one at the index date. Patients with 
any chronic respiratory disease other than asthma at any time were 
excluded from the study. 
Outcome measures and statistical analyses
We analyzed three composite endpoints derived from database 
markers of asthma control during both baseline and outcome years. The 
first was evidence of an exacerbation, which we defined as a prescribed 
course of oral corticosteroids or an asthma-related hospital attendance 
or admission, Accident and Emergency (A and E) attendance, or out-
of-hours attendance (as per American Thoracic Society/European 
Respiratory Society recommendations [13]), or a General Practice (GP) 
consultation for lower respiratory tract infection (LRTI). We defined 
asthma-related events as all events with a lower respiratory code in the 
database. 
The second key endpoint was no loss of asthma control, which 
we defined as no exacerbation (as above) and no hospital outpatient 
department attendance for asthma. A third measure, no loss of asthma 
control plus limited SABA use, we defined as no loss of asthma control 
(as above) plus a mean daily SABA dose of albuterol ≤ 200 µg/day (≤ 
2 puffs/day) or terbutaline ≤ 500 µg/day. We included SABA use as an 
indicator of asthma symptoms, thus the measure served as a proxy for 
the Global Initiative for Asthma (GINA) definition of control [2].
Adherence to ICS was calculated from recorded prescriptions in the 
database as the ratio of the doses contained in prescribed refills to the 
annual number of doses required by the prescription. The controller-
to-total asthma medication ratio was defined as the number of units 
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Pe
rc
en
ta
ge
 o
f p
ati
en
ts
No exacerbation No loss of
asthma control
No loss of
control + limited
SABA
No asthma
consultations
0-3 primary care
consultations
Baseline year
Year after step-
down
73% 73%
47%
39%
28%
48%47%
64%
81% 81%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Pe
rc
en
ta
ge
 o
f p
ati
en
ts
No exacerbation No loss of
asthma control
No loss of
control + limited
SABA
No asthma
consultations
0-3 primary care
consultations
Baseline year
Year after step-
down
77% 76%
67% 67%
40%
37% 39% 36%
26%
58%
Figure 1: Asthma-related measures for the ICS cohorts during the baseline 
year and the year after step-down in ICS dose to a once-daily regimen (A) 
or a twice-daily regimen (B). All measures improved significantly between 
baseline and post step-down (p<0.001) with the exception of the composite 
database measure of no loss of asthma control plus limited SABA use, which 
was comparable in the QD cohort and fell significantly (p<0.001) in the BD 
cohort.
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of controllers/(units of controllers + units of relievers), denoting ICS 
as the controller, SABA as the reliever, and one unit as one inhaler 
[14,15]. We also tabulated the use of respiratory resources including 
prescriptions for asthma therapy (ICS, LABA, SABA, and leukotriene 
receptor antagonists (LTRAs)), healthcare professional consultations 
for asthma or LRTI, asthma-related hospitalizations and A and E 
attendance.
Separate analyses were carried out for each treatment population 
(ICS and ICS/LABA). Summary statistics were used to characterize 
the two ICS cohorts (step-down to QD or BD) and the two ICS/LABA 
cohorts (step-down to QD or BD). Patient profiles were compared 
within each treatment cohort for the baseline year versus the year after 
step-down using the Wilcoxon signed rank test (for variables measured 
on the interval scale), the McNemar test (for binary variables), or 
the marginal homogeneity test (for ordinal variables) to account for 
repeated measurements for each patient.
Univariate logistic regression models were used to determine which 
demographic factors, comorbidities, and baseline characteristics were 
individually predictive of a loss of asthma control during the year after 
step-down for all patients with no loss of asthma control during the 
prior (baseline) year. We selected non-collinear predictive factors and 
used multivariate logistic regression modeling to determine which 
factors were predictive of a loss of asthma control, when adjusted for all 
other non-collinear effects, with the dichotomous status for the no loss 
of asthma control measure as the dependent variable.
Analyses were performed using SPSS version 18 (IBM UK Ltd, 
North Harbour Portsmouth, Hampshire, UK), SAS version 9.2 (SAS 
UK, Marlow, Buckinghamshire, UK), and Microsoft office Excel 2007 
(Microsoft UK, Reading, Berkshire, UK). We defined statistically 
significant results as p<0.05.
Results
Patients prescribed ICS
From almost 7 million patients receiving ICS who were included in 
the GPRD and OPCRD during the study period, we identified 26,834 
eligible patients (Supplementary Figure 1) who were prescribed BD ICS 
during the baseline year and who on the index date were stepped down 
in dose by ≥ 50% and either switched to a QD ICS regimen (n=941; 
3.5%) or remained on a BD ICS regimen (n=25,893; 96.5%).
There were several significant differences in demographic and 
baseline year characteristics between the QD and BD cohorts (Table 
1 and supplementary table 1). Patients in the QD cohort tended to be 
older than those in the BD cohort and were less likely to be current 
smokers or to have taken acetaminophen during the baseline year. 
Asthma control was better during the baseline year in the QD cohort, 
as indicated by fewer exacerbations and the percentages of patients 
who met our composite database measures of asthma control (Table 1). 
The median daily ICS dose was lower in the QD than the BD cohort at 
baseline (Table 1). In addition, almost half (48%) of patients in the QD 
cohort were stepped down in ICS dose by >50%, as compared with 22% 
of those in the BD cohort; and the index date doses of ICS were lower 
in the QD cohort (Table 2). The mean index date was 1 year later for 
patients stepped down to a QD regimen.
During the year after step-down, fewer than 10% of patients in 
each cohort were prescribed a second controller: 43 (4.6%) and 1688 
(6.5%) of patients in QD and BD cohorts, respectively, received one or 
more prescriptions for a LABA; 37 (3.9%) and 475 (1.8%), respectively, 
were prescribed an LTRA. However, the ICS dose was increased for 
368 (39.1%) of patients in the QD cohort and 9523 (36.8%) of those 
in the BD cohort. Irrespective of dosing regimen, patients in the ICS 
cohorts were significantly more likely to have no exacerbations; no GP 
consultations for LRTI; no asthma consultations, and only 0-3 primary 
care consultations in the year after step-down in ICS dose, as compared 
with baseline (Figure 1 and table 3). Moreover, a greater proportion of 
patients, as compared with baseline, had no loss of asthma control after 
step-down in both QD and BD cohorts (Figure 1). Adherence improved 
after step-down, most markedly in the QD cohort, resulting in higher 
consumed ICS daily dose over the year than during the baseline year 
(based on prescriptions/year) despite the prescribed step-down in 
daily ICS dose (Table 3). In both cohorts the median (IQR) number 
of ICS prescriptions increased from 2 (1-4) during the baseline year 
to 4 (3-6) during the year after step-down. Median SABA daily doses 
also increased during the outcome year (Table 3); therefore, the no-
loss of asthma control measure incorporating limited SABA use did 
not improve. However, the mean controller-to-total medication ratio 
improved in both cohorts after step-down, suggesting that patients 
were not using excessive reliever therapy in place of controller therapy.
Using multiple logistic regression modeling, and considering all 
significant non-collinear factors identified in the univariate model, 
we identified several demographic and clinical baseline factors that 
predicted a loss of asthma control in the year after ICS dose step-down 
for patients who had no loss of asthma control during the baseline 
year before step-down (Table 4). We found that female patients, obese 
patients, smokers, and patients with a recorded GERD diagnosis and/
or receiving therapy for GERD were more likely to lose asthma control. 
Moreover, patients with an earlier step-down date, or who, during the 
baseline year, received seven or more SABA prescriptions or had more 
than three primary care consultations were more likely to lose control. 
The time of diagnosis or first evidence of asthma was collinear with 
the step-down year and could replace it in the model. Similarly, the 
number of SABA prescriptions was collinear with the number of ICS 
prescriptions and the number of asthma prescriptions; either of the 
latter variables could replace SABA prescriptions in the model. The 
dosing regimen after step-down (QD vs. BD) was not a predictive factor 
for loss of asthma control.
Patients prescribed ICS/LABA
We identified 20,814 patients who were prescribed BD ICS/LABA 
during the baseline year and were switched after ICS dose step-down to 
a QD regimen (n=505; 2.4%) or remained on a BD regimen (n=20,309; 
97.6%; Supplementary Figure 1). 
Patients in the QD and BD cohorts were similar demographically 
with the exception of socioeconomic status, which was higher, thus 
better, in the QD cohort (Table 1 and supplementary table 1). Asthma 
control measures differed, however: in the QD cohort, significantly 
more patients had no loss of asthma control; fewer were prescribed oral 
corticosteroids; fewer had asthma consultations; and the median ICS 
doses consumed during the baseline year and prescribed at step-down 
were lower than in the BD cohort (Table 1).
During the year after step-down, not all patients were prescribed 
a second controller: 216 (42.8%) and 11,217 (55.2%) of patients in QD 
and BD cohorts, respectively, received one or more prescriptions for a 
LABA (separate or in fixed-dose combination with ICS); 85 (16.8%) 
and 2424 (11.9%), respectively were prescribed an LTRA. The ICS 
dose was increased for 240 (47.5%) of patients in the QD cohort and 
9734 (47.9%) of those in the BD cohort. The comparisons between the 
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ICS cohorts (n=26,834) ICS/LABA cohorts (n=20,814)
Characteristic Switch to QD
 (n=941)
Remain on BD
 (n=25,893)
p value* Switch to QD
 (n=505)
Remain on BD
 (n=20,309)
p value*
Female sex, n (%) 498 (52.9) 14,250 (55.0) 0.201 327 (64.8) 12,353 (60.8) 0.074
Age at index date, median (IQR) 32 (12-49) 26 (10-47) <0.001 44 (24-56) 42 (24-55) 0.560
4-11 years, n (%) 226 (24.0) 7994 (30.9) <0.001 55 (10.9) 2155 (10.6) 0.380
12-60 years, n (%) 636 (67.6) 16,018 (61.9) 373 (73.9) 15,472 (76.2)
61-80 years (all nonsmokers), n (%) 79 (8.4) 1881 (7.3) 77 (15.2) 2682 (13.2)
BMI (kg/m2), mean (SD)† 25.2 (6.4) 25.1 (7.3) 0.164 26.8 (6.7) 27.1 (6.8) 0.238
Underweight (BMI <18.5 kg/m2), n (%) 101 (14.4) 3242 (17.5) 0.193 37 (8.5) 1316 (7.5) 0.719
Normal BMI (18.5-24.49 kg/m2), n (%) 257 (36.6) 6620 (35.7) 151 (34.6) 5843 (33.1)
Overweight (BMI 25-29.99 kg/m2), n (%) 200 (28.5) 4955 (26.7) 130 (29.7) 5553 (31.5)
Obese (BMI ≥ 30 kg/m2), n (%) 144 (20.5) 3734 (20.1) 119 (27.2) 4942 (28.0)
Recorded smoking status, n (%) 877 (93.2) 23,674 (91.4) 484 (95.8) 19,721 (97.1)
Current smoker 181 (20.6) 5965 (25.2) 0.007 103 (21.3) 3970 (20.1) 0.822
Ex-smoker 226 (25.8) 5496 (23.2) 97 (20.0) 4029 (20.4)
Non-smoker 470 (53.6) 12,213 (51.6) 284 (58.7) 11,722 (59.4)
Socioeconomic status, median (IQR)‡ 17.7 (8.4-41) 17.9 (9.4-33.9) 0.438 23.4 (11.2-42.0) 17.9 (8.8-33.0) 0.004
Recorded comorbidity/treatment, n (%)§
Rhinitis 303 (32.2) 8057 (31.1) 0.481 170 (33.7) 6802 (33.5) 0.936
Cardiac disease 187 (19.9) 4713 (18.2) 0.193 141 (27.9) 5612 (27.6) 0.886
Gastroesophageal reflux disease 140 (14.9) 3213 (12.4) 0.024 118 (23.4) 4690 (23.1) 0.886
≥ 1 prescription prior 12 months (%)
NSAID 138 (14.7) 3677 (14.2) 0.689 119 (23.6) 4244 (20.9) 0.146
Beta blocker 16 (1.7) 500 (1.9) 0.613 3 (0.6) 343 (1.7) 0.057
Acetaminophen 157 (16.7) 5108 (19.7) 0.021 137 (27.1) 5051 (24.9) 0.247
Daily ICS dose (μg/d), median (IQR)ǁ 164 (99-329) 219 (110-384) <0.001 329 (164-756) 395 (164-822) 0.009
Mean daily ICS dose, n (%)
1-100 μg/d 245 (26) 5216 (20.1) <0.001 81 (16.0) 2246 (11.1) 0.010
101-200 μg/d 275 (29.2) 7594 (29.3) 89 (17.6) 3597 (17.7)
201-400 μg/d 231 (24.5) 6743 (26.0) 108 (21.4) 4352 (21.4)
401-800 μg/d 134 (14.2) 4361 (16.8) 109 (21.6) 4955 (24.4)
≥ 801 μg/d 56 (6.0) 1979 (7.6) 118 (23.4) 5159 (25.4)
Concomitant LTRA, n (%) 26 (2.8) 287 (1.1) <0.001 78 (15.4) 1946 (9.6) <0.001
No. SABA scripts, median (IQR) 2 (1-4) 2 (1-4) <0.001 3 (1-5) 3 (1-7) <0.001
Mean daily SABA dose, n (%)ǁ
0-100 μg/d 335 (35.6) 7764 (30.0) <0.001 134 (26.5) 4386 (21.6) <0.001
101-200 μg/d 260 (27.6) 7032 (27.2) 121 (24.0) 4022 (19.8)
201-400 μg/d 188 (20) 5844 (22.6) 131 (25.9) 4980 (24.5)
≥401 μg/d 158 (16.8) 5253 (20.3) 119 (23.6) 6921 (34.1)
No loss of asthma control, n (%)¶ 685 (72.8) 17,330 (66.9) <0.001 298 (59.0) 11,040 (54.4) 0.038
No loss of asthma control + limited SABA, 
n (%)¶
442 (47.0) 10,354 (40.0) <0.001 174 (34.5) 5181 (25.5) <0.001
Total exacerbations, n (%)¶
0 690 (73.3) 17,452 (67.4) <0.001 303 (60.0) 11,135 (54.8) 0.054
1 177 (18.8) 5263 (20.3) 102 (20.2) 4385 (21.6)
≥ 2 74 (7.9) 3178 (12.3) 100 (19.8) 4789 (23.6)
Primary care consultations, n (%)
0-3 259 (27.5) 6747 (26.1) 0.226 73 (14.5) 3249 (16.0) 0.494
4-5 167 (17.7) 4574 (17.7) 78 (15.4) 2743 (13.5)
6-8 220 (23.4) 5625 (21.7) 101 (20.0) 4060 (20.0)
9-13 166 (17.6) 5315 (20.5) 110 (21.8) 4829 (23.8)
≥14 129 (13.7) 3632 (14.0) 143 (28.3) 5428 (26.7)
*The Mann-Whitney U test was used to compare continuous variables and the χ2 test, categorical variables. 
†Weight and height to calculate BMI were available for 702 (74.6%) and 18,529 (71.6%) of patients in ICS QD and BD cohorts, respectively, and 437 (86.5%) and 17,651 
(86.9%) of patients in ICS/LABA QD and BD cohorts, respectively.
‡The socioeconomic status is the Index of Multiple Deprivation score linked to each practice postcode.
§Patients with rhinitis, cardiac disease, and GERD included those with a recorded diagnosis or recorded therapy for same.
ǁThe ICS dose is the beclomethasone dipropionate-equivalent, and the SABA dose is the albuterol equivalent.
¶Composite database measure (defined in text).
BD: Twice Daily; BMI: Body Mass Index; ICS: Inhaled Corticosteroid; IQR: Interquartile Range; LABA: Long-Acting β-Agonist; LTRA: Leukotriene Receptor Antagonist; 
NSAID: Non-steroidal Anti-Inflammatory Drug; QD: Once Daily; SABA: Short-Acting β-Agonist
Table 1: Baseline year characteristics of the ICS and ICS/LABA cohorts.
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baseline year and the year after step-down resembled those for patients 
in the ICS population: in both QD and BD cohorts, the proportions 
of patients with no exacerbations; no GP consultations for LRTI; no 
asthma consultations, and only 0-3 primary care consultations were 
significantly higher in the year after ICS dose step-down, as compared 
with baseline (Figure 2 and table 3). The proportion of patients with 
no loss of asthma control increased from baseline but not significantly 
in the QD cohort, while in the BD cohort the proportion increased 
significantly from baseline for both asthma control measures (Figure 
2). Adherence improved after step-down for both cohorts, resulting in 
significantly higher consumed ICS daily dose in the BD cohort despite 
the prescribed step-down (Table 3). Increased adherence was most 
marked in patients stepped down to QD therapy.
Baseline factors that predicted a loss of asthma control in the year 
after ICS dose step-down for patients who had no loss of asthma control 
during the baseline year are listed in table 5. Older patients, those with 
an earlier step-down date, those with recorded rhinitis or GERD, those 
who received acetaminophen, and those who received two or more 
SABA prescriptions during the baseline year were more likely to lose 
asthma control, as were patients who had more than three primary care 
consultations or consumed ICS >800 µg/day during the baseline year. 
As for the ICS population, the dosing regimen after step-down (QD vs. 
BD) was not a predictive factor for loss of asthma control.
Discussion
The results of this real-life observational study indicate that stepping 
down ICS dose is a valid management option and may improve asthma-
related outcomes in the UK primary care setting. Patients in both ICS 
and ICS/LABA cohorts showed significant improvements in most 
database markers of asthma control during the year after step-down, as 
compared with the baseline year. Moreover, we found that adherence to 
controller therapy improved significantly in all treatment cohorts after 
step-down. Improvements were recorded in asthma control markers 
and adherence irrespective of whether patients were stepped down from 
the BD baseline regimen to a QD or BD frequency of administration 
during the year after step-down.
ICS cohorts (n=26,834) ICS/LABA cohorts (n=20,814)
Characteristic Switch to QD
 (n=941)
Remain on BD
 (n=25,893)
p value* Switch to QD
 (n=505)
Remain on BD
 (n=20,309)
p value*
Year of index prescription, mean (SD) 2000.8 (4.7) 1999.6 (4.3) <0.001 2003.4 (3.6) 2003.2 (3.3) 0.002
ICS drug prescribed at the index date
Beclomethasone 353 (37.5) 18,249 (70.5) <0.001 48 (9.5) 5474 (27.0) <0.001
Fluticasone 130 (13.8) 2790 (10.8) 184 (36.4) 9309 (45.8)
Mometasone 53 (5.6) 10 (0.0) 20 (4.0) 19 (0.1)
Budesonide 272 (28.9) 4841 (18.7) 126 (25.0) 5495 (27.1)
Ciclesonide 133 (14.1) 3 (0.0) 127 (25.1) 12 (0.1)
ICS dose† prescribed at the index date, n (%)
≤ 200 µg/day 748 (79.5) 13,758 (53.1) <0.001 331 (65.5) 5091 (25.1) <0.001
201-400 µg/day 145 (15.4) 10,100 (39.0) 75 (14.9) 8827 (43.5)
>400 µg/day 48 (5.1) 2035 (7.9) 99 (19.6) 6391 (31.5)
Percentage step-down in ICS dose, n (%)
50% 493 (52.4) 20,093 (77.6) <0.001 237 (46.9) 12,079 (59.5) <0.001
>50% 448 (47.6) 5800 (22.4) 268 (53.1) 8230 (40.5)
*χ2 test; †The ICS dose is the beclomethasone dipropionate-equivalent.
BD: Twice Daily; ICS: Inhaled Corticosteroid; LABA: Long-Acting β-Agonist; QD: Once Daily
Table 2: Inhaled corticosteroid drug and dose prescribed on the index date when patients were stepped down by ≥ 50% in ICS dose.
ICS cohorts
QD cohort (n=941) BD cohort (n=25,893)
Characteristic Baseline year Year after step-down p value Baseline year Year after step-down p value
No consultation for LRTI, n (%) 803 (85.3) 845 (89.8) 0.002‡ 21,409 (82.7) 22,709 (87.7) <0.001‡
Daily ICS dose (μg/d), median (IQR) 164 (99-329) 219 (137-384) <0.001* 219 (110-384) 274 (164-493) <0.001*
ICS adherence ≥70%, n (%) 440 (46.8) 710 (75.5) <0.001† 13,495 (52.1) 16,184 (62.5) <0.001†
Spacer device used, n (%) 106 (11.3) 71 (7.5) 0.003‡ 4630 (17.9) 3221 (12.4) <0.001‡
Daily SABA dose (μg/d), median (IQR) 110 (55-274) 164 (55-329) <0.001* 164 (55-329) 219 (110-438) <0.001*
Controller: total asthma med ratio, mean (SD) 0.58 (0.25) 0.60 (0.20) <0.001* 0.54 (0.24) 0.60 (0.20) <0.001*
ICS/LABA cohorts
QD cohort (n=505) BD cohort (n=20,309)
No consultation for LRTI, n (%) 406 (80.4) 419 (83.0) 0.287‡ 15,939 (78.5) 16,796 (82.7) <0.001‡
Daily ICS dose (μg/d), median (IQR) 329 (164-756) 362 (210-712) 0.280* 395 (164-822) 460 (247-855) <0.001*
ICS adherence ≥ 70%, n (%) 297 (58.8) 399 (79.0) <0.001† 13,019 (64.1) 13,731 (67.6) <0.001†
Spacer device used, n (%) 70 (13.9) 69 (13.7) 1.0‡ 3975 (19.6) 2799 (13.8) <0.001‡
Daily SABA dose (μg/d), median (IQR) 186 (55-384) 219 (110-438) 0.086* 219 (110-548) 219 (110-548) 0.001*
Controller: total asthma med ratio, mean (SD) 0.60 (0.26) 0.60 (0.20) 0.002* 0.54 (0.27) 0.60 (0.20) <0.001*
*Wilcoxon signed rank test; †marginal homogeneity test; ‡McNemar test
BD: Twice Daily; IQR: Interquartile Range; LABA: Long-Acting β-Agonist; LRTI: Lower Respiratory Tract Infection; QD: Once Daily; SABA: Short-Acting β-Agonist 
Table 3: Baseline year measures vs. the year after step-down in inhaled corticosteroid (ICS) dose.
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Drawing retrospectively on two similarly structured databases 
enabled us to characterize and examine real-life outcomes for over 
47,000 patients who had received usual care for asthma at UK primary 
care practices. Following patients for 2 full years enabled us to examine 
clinical characteristics over the baseline year before step-down in 
addition to database measures of asthma control over a full year after 
step-down, thereby eliminating the influence of seasonal variations in 
asthma symptoms. These findings provide descriptive information on 
the use of management options that are recommended in best practice 
guidelines but remain poorly understood. Interestingly, despite the large 
patient numbers, our study population represents a small proportion of 
patients in the CPRD and OPCRD who are receiving ICS for asthma, 
suggesting that ICS dose is not frequently stepped down.
This study does not provide information on the deciding factors 
for step-down, namely, precisely why prescribing physicians decided 
to decrease ICS dose by ≥ 50%. Over the course of the baseline year, 
only 67% and 55% of patients in ICS and ICS/LABA populations, 
respectively, met the database measure of no loss of asthma control; 
and the percentages of patients who met the more stringent asthma 
control measure limiting SABA use were even lower (40% and 26%, 
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Figure 2: Asthma-related measures for the ICS/LABA cohorts during the 
baseline year and the year after step-down in ICS dose to a once-daily 
regimen (A) or a twice-daily regimen (B). In the QD cohort, the number 
of exacerbations and asthma and primary care consultations decreased 
significantly between baseline and post step-down (p ≤ 0.04). In the BD 
cohort, all measures improved significantly between baseline and post step-
down (p<0.001).
Category Odds Ratio (95% CI) P value
Normal BMI (18.5-24.49 m/kg2) 1.00
vs. Underweight (<18.5 m/kg2) 1.05 (0.90-1.22) 0.010
vs. Overweight (25-29.99 m/kg2) 1.12 (0.99-1.26)
vs. Obese (≥30 m/kg2) 1.25 (1.10-1.42)
Female 1.00 0.002
vs. Male 0.85 (0.77-0.95)
Non-smoker 1.00 0.005
vs. Current smoker 1.13 (1.002-1.28)
vs. Ex-smoker 0.91 (0.80-1.03)
Year of step-down date (later vs. earlier) 0.88 (0.84-0.93) <0.001
No GERD diagnosis and/or drugs 1.00 <0.001
vs. GERD diagnosis and/or drugs 1.39 (1.23-1.58)
0-1 SABA prescriptions/year 1.00 <0.001
vs. 2-3/year 1.03 (0.92-1.16)
vs. 4-6/year 1.14 (0.996-1.31)
vs. ≥7/year 1.41 (1.22-1.62)
0-3 primary care consultations/year 1.00 <0.001
vs. 4-5/year 1.27 (1.09-1.47)
vs. 6-8/year 1.31 (1.14-1.52)
vs. 9-13/year 1.73 (1.49-1.99)
vs. ≥14/year 1.82 (1.55-2.14)
*Composite database measure (defined in text)
BMI: Body Mass Index; GERD: Gastroesophageal Reflux Disease; ICS: Inhaled 
Corticosteroid; SABA: Short-acting β-Agonist
Table 4: Demographic and baseline factors predictive of loss of asthma control 
during the year after ICS dose step-down for all patients in the ICS cohorts who met 
the composite database measure of no loss of asthma control* during the baseline 
year (n=18,015): A multivariate model.
Category Odds Ratio (95% CI) p value
Age (older vs. younger) 1.01 (1.00-1.01) <0.001
Year of step-down date (later vs. earlier) 0.89 (0.83-0.95) <0.001
No rhinitis diagnosis and/or drugs 1.00 0.001
vs. rhinitis diagnosis and/or drugs 1.18 (1.07-1.30)
No GERD diagnosis and/or drugs 1.00 <0.001
vs. GERD diagnosis and/or drugs 1.27 (1.13-1.42)
No acetaminophen prescription 1.00 <0.001
vs. yes acetaminophen prescription 1.20 (1.07-1.34)
0-1 SABA prescriptions/year 1.00 <0.001
vs. 2-3/year 1.17 (1.02-1.34)
vs. 4-6/year 1.27 (1.11-1.46)
vs. ≥7/year 1.46 (1.29-1.66)
ICS dose 1-100 µg/day 1.00 0.031
vs. 101-200 µg/day 1.10 (0.92-1.31)
vs. 201-400 µg/day 0.995 (0.84-1.18)
vs. 401-800 µg/day 1.16 (0.99-1.37)
vs. >800 µg/day 1.21 (1.02-1.43)
0-3 primary care consultations/year 1.00 <0.001
vs. 4-5/year 1.41 (1.20-1.65)
vs. 6-8/year 1.61 (1.39-1.87)
vs. 9-13/year 1.83 (1.58-2.12)
vs. ≥ 14/year 1.92 (1.65-2.24)
*See text for definition.
GERD: Gastroesophageal Reflux Disease; ICS: Inhaled Corticosteroid; LABA: 
Long-Acting β-Agonist; SABA: Short-Acting β-Agonist
Table 5: Demographic and baseline factors predictive of loss of asthma control 
during the year after ICS dose step-down for all patients in the ICS/LABA cohorts 
who met the composite database measure of no loss of asthma control* during the 
baseline year (n=11,338): A multivariate model.
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respectively). Presumably, therefore, all patients were doing well 
during the period immediately preceding the step-down date even if 
their asthma was not well-controlled during the entire baseline year. 
A study limitation is that our retrospective assessments of asthma 
control necessarily are restricted to recorded data such as consultations, 
hospitalizations, and prescriptions and do not include either subjective 
measures, such as patient-reported quality of life, or objective measures 
that are infrequently recorded in primary care, such as lung function 
and inflammatory markers. 
Several small studies have found that lung function tests and 
parameters of airway inflammation, particularly sputum eosinophil 
count, can be useful for individualizing step-down strategies and 
monitoring patients [16-20]; these tests, however, may be impractical in 
the primary care setting where most patients with asthma are managed 
[21]. In a recent study, Clearie et al. [17] were able to significantly 
step down ICS dose for 119 of 150 (79%) community-based patients 
without any worsening of airways inflammation or lung function. They 
hypothesized that successful step-down may be the result of enhanced 
adherence because of the supervised step-down. 
We also found improved adherence after step-down and speculate 
that a similar mechanism could be operative in our study. Patients 
may better accept their asthma care and better self-regulate if they are 
involved in the decision to step down dose. Adherence improved most 
dramatically in the QD cohorts-to ≥ 70% for more than three quarters 
of patients-perhaps because of a simplified dosing regimen. Indeed 
one could argue that we detected a step-up effect, since the median 
consumed dose of ICS increased during the year after the prescribed 
step-down in dose. An explanation for this finding could be that there 
was better patient supervision during the step-down process, which, 
if true, would indicate that better patient supervision can result in 
improved asthma control. 
For patients on combination therapy with ICS/LABA, the results of 
several studies suggest that asthma control is better maintained if the 
ICS dose is tapered while LABA is continued [5,22-24]. By contrast, 
in the Clearie et al. study [17], 18 of 21 patients receiving concomitant 
LABA were able to discontinue it successfully before tapering ICS. Their 
study procedure was to discontinue concomitant controller therapy (eg, 
LABA) and then halve the ICS dose every 2 weeks until patients became 
unstable or reached a BDP-equivalent dose of ≤ 200 µg/day; patients 
whose asthma became unstable stepped back up to the last stable dose 
of ICS. In our study, 6.5% of patients in the ICS cohorts were prescribed 
a LABA, and 2% were prescribed an LTRA, during the year after step-
down; in the ICS/LABA cohorts, 55% and 12% were prescribed a LABA 
or an LTRA, respectively, after step-down.
This study identified several factors predictive of loss of asthma 
control after step-down for previously controlled patients. Most of 
the factors we identified are considered to be either risk factors for 
or indicators of poor asthma control [1-3,25-27]. Predictive factors 
common to both ICS and ICS/LABA populations were comorbid 
GERD and, during the baseline year, seven or more SABA prescriptions 
and four or more primary care consultations. In the ICS cohort, an 
earlier index date (or longer asthma duration), female sex, obesity, and 
smoking also significantly raised the odds of loss of asthma control 
after step-down; in the ICS/LABA population, additional significant 
factors were older age, comorbid rhinitis, and, during the baseline 
year, a prescription for acetaminophen or mean consumed ICS dose 
of >800 µg/day. These factors are important clinically and consistent 
with previous research especially for rhinitis, high SABA use, and 
acetaminophen, as they could be considered markers of patients at risk 
of poor outcomes and who may require closer monitoring and clinical 
attention [25-27]. Further research is needed to examine outcomes for 
these patients after step-down in ICS dose. A prior study found that for 
patients with mild asthma who discontinue controller therapy, older 
age and longer asthma duration were the best predictors of symptom 
recurrence [28].
We did not compare results for patients in the QD and BD cohorts 
as this was not part of our a priori analysis plan; however, improvements 
in asthma control and adherence were numerically similar for QD and 
BD cohorts in the year after step-down. Moreover, the regimen after 
step-down (QD vs. BD) was not a predictive factor for loss of asthma 
control. However, patients who were stepped down to a QD regimen 
represented a small proportion of studied patients (3.5% and 2.4% of 
ICS and ICS/LABA populations, respectively).The baseline data suggest 
that for both ICS and ICS/LABA populations, asthma was generally 
better controlled at baseline in patients stepped down to QD rather 
than BD administration. Moreover, in the ICS population, patients in 
the QD cohort were older and less likely to smoke than those in the 
BD cohort; in the ICS/LABA population, socioeconomic status was the 
only demographic difference between cohorts (higher SES in the QD 
cohort).
In conclusion, the results of this study suggest that stepping down 
therapy is a valid management option and may improve asthma-related 
outcomes. Stepping down therapy from a BD to a QD regimen does 
not lead to loss of asthma control. The improvements seen in our study 
may be the result of increased adherence, particularly among patients 
switched to QD therapy. Additional larger studies are required to 
understand for which patients, and when, to step down existing therapy.
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